1. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
- Author
-
Moura LG, Tognon R, Nunes NS, Rodrigues LC, Ferreira AF, Kashima S, Covas DT, Santana M, Souto EX, Perobelli L, Simões BP, Dias-Baruffi M, and Castro FA
- Subjects
- Adult, Amino Acid Substitution, Antigens, CD34 genetics, Blood Proteins, Bone Marrow pathology, Bone Marrow Neoplasms diagnosis, Bone Marrow Neoplasms genetics, Bone Marrow Neoplasms metabolism, Cell Line, Galectin 1 metabolism, Galectin 3 metabolism, Galectins, Gene Expression Regulation, Neoplastic, Humans, Janus Kinase 2 metabolism, Male, Middle Aged, Mutation, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders genetics, Myeloproliferative Disorders metabolism, Polycythemia Vera diagnosis, Polycythemia Vera metabolism, Primary Myelofibrosis diagnosis, Primary Myelofibrosis metabolism, Thrombocythemia, Essential diagnosis, Thrombocythemia, Essential metabolism, Galectin 1 genetics, Galectin 3 genetics, Janus Kinase 2 genetics, Polycythemia Vera genetics, Primary Myelofibrosis genetics, Thrombocythemia, Essential genetics
- Abstract
Despite all the knowledge, the cellular and molecular mechanisms involved in myeloproliferative neoplasm (MPN) pathophysiology remain unclear. Authors have shown galectin-1 (Gal-1) and 3 playing roles in tumour angiogenesis and fibrosis, which were correlated with poor prognosis in patients with MPN. In the present study LGALS1 and LGALS3 were differently expressed between polycythemia vera, essential thrombocythemia (ET) and primary myelofibrosis (PMF) diseases. Increased LGALS3 expression was associated with a negative JAK2 V617F status mutation in leucocytes from PMF but not in patients with ET without this mutation. However, a positive Janus kinase 2 (JAK2) V617F cell line established from patients with ET (SET-2 cells) when treated with JAK inhibitor presented high levels of LGALS3. Additionally, high LGALS1 expression was found in CD34(+) cells but not in leucocytes from patients with PMF, in absence of JAK2 V617F mutation, and also in SET-2 cells treated with JAK inhibitor. Thus, our findings indicate that differential expression of LGALS1 and/or LGALS3 in patients with MPN is linked with JAK2 V617F status mutation in these diseases and state of cell differentiation., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF